Tirzepatide is the compound most people serious about weight loss are switching to right now. It is stronger than semaglutide, it beat it in a direct head-to-head trial, and it is FDA-approved and available. It hits a second hormone pathway on top of the one semaglutide uses, and that addition is what drives the bigger numbers. Here is the full breakdown: what it is, how it works, the actual dose schedule, the trial data, and how it compares to its main rival.

What is tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist given as a once-weekly subcutaneous injection. It is sold as Zepbound for weight management and Mounjaro for type 2 diabetes (the same molecule under two names). Where semaglutide activates the single GLP-1 pathway, tirzepatide adds a second incretin receptor, GIP, which is why it is described as a dual agonist and why its effects run stronger. It has a half-life of about five days.

How it works

Tirzepatide produces the same core appetite-suppressing effect as semaglutide, reduced hunger, increased fullness, slower gastric emptying, so the main thing a person feels is eating less without battling cravings. The difference is that it engages two incretin receptors at once rather than one. By activating both GIP and GLP-1, it achieves greater glycemic control and greater weight loss than GLP-1-only agents in head-to-head trials. The practical translation is a stronger version of the same appetite-driven mechanism, not a different kind of action.

The evidence

Tirzepatide's pivotal weight-loss trial, SURMOUNT-1, reported an average weight loss of about 20.9 to 22.5% at the maximum dose over 72 weeks, the largest weight reduction seen in a Phase 3 obesity trial at the time of publication. More importantly for anyone choosing between the two, SURMOUNT-5 was a direct head-to-head against semaglutide, and tirzepatide won, producing about 20.2% versus 13.7% for Wegovy-dose semaglutide. That is the single most useful piece of evidence in the semaglutide-versus-tirzepatide decision, because it is a true comparison rather than two separate trials with different designs. The combination of a higher ceiling and a won head-to-head is why tirzepatide is the current pick for most people who want maximum effect from an approved, available compound.

Dosing

Tirzepatide follows a structured four-week escalation, the same slow-ramp logic as semaglutide, to let the body adjust and reduce GI side effects.

The schedule starts at 2.5 mg once weekly for the first four weeks, then increases by 2.5 mg every four weeks as tolerated: 2.5 mg, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to a 15 mg maximum, reaching the top dose around week 21. Not everyone goes to 15 mg; providers hold at a lower dose if appetite suppression is already working or if side effects need more time to settle. One important practical rule: anyone switching from semaglutide always starts tirzepatide at 2.5 mg regardless of their previous semaglutide dose, because there is no direct mg-to-mg conversion between the two and the dual mechanism means the body still needs to adjust.

Timeline

As with the rest of the class, appetite effects show up within the first couple of weeks while the headline weight loss accumulates over many months. The SURMOUNT-1 figure is a 72-week result reached after a months-long titration to the maximum dose, so it reflects more than a year of continuous use, not a quick outcome.

Side effects

The side-effect profile is the same GI-dominant family as semaglutide, nausea and related gastrointestinal effects, worst during dose increases, and it is generally tolerated about as well or slightly better than semaglutide. The shorter half-life and the structured four-week escalation are the practical levers for managing tolerability, and holding a dose longer is a common adjustment when side effects need more time to resolve.

Where it fits

Tirzepatide is the strongest approved-and-available weight loss compound, the one for someone who wants maximum effect with FDA approval and trial data behind it, or who tried semaglutide and found it too weak or stalled on it. It carries the same GI side-effect considerations as the rest of the class and the same chronic-use framing, the weight loss is tied to continued treatment. Between the two dominant GLP-1 options, tirzepatide is the higher-ceiling choice with a head-to-head win to back it, while semaglutide remains the more established, longer-tracked name. For most people prioritizing results from an approved compound, tirzepatide is the current answer.